Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 11/20 | 0.92 |
| ▸ | MMP2 | P08253 | 10/20 | 0.92 |
| ▸ | MMP3 | P08254 | 7/20 | 0.92 |
| ▸ | MMP13 | P45452 | 7/20 | 0.92 |
| ▸ | MMP1 | P03956 | 6/20 | 0.92 |
| ▸ | MMP7 | P09237 | 6/20 | 0.92 |
| ▸ | MMP8 | P22894 | 1/20 | 0.92 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.74 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.74 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.74 |
| ▸ | ADAMTS4 | O75173 | 7/20 | 0.73 |
| ▸ | MMP14 | P50281 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2161549 | 1.00 | MMP9 (0.92) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL5839717 | 1.00 | MMP9 (0.92) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL7761520 | 0.96 | MMP2 (1.00) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL7761532 | 0.96 | MMP2 (1.00) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL7341651 | 0.90 | MMP2 (0.75) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL7341649 | 0.90 | MMP2 (0.75) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL7341646 | 0.90 | MMP2 (0.75) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL6723666 | 0.88 | MMP9 (0.72) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL6723663 | 0.88 | MMP9 (0.72) | MMP9MMP2MMP3MMP13MMP1 | |
| SCHEMBL7347163 | 0.88 | MMP9 (0.72) | MMP9MMP2MMP3MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227792-A1 | CARBORANE HYDROXAMIC ACID MATRIX METALLOPROTEINASE AGENTS FOR BORON NEUTRON CAPTURE THERAPY | LOYOLA UNIVERSITY OF CHICAGO | 2022-07-21 | — | — | US | disclosed |
| WO-2020252439-A1 | CARBORANE HYDROXAMIC ACID MATRIX METALLOPROTEINASE AGENTS FOR BORON NEUTRON CAPTURE THERAPY | LOYOLA UNIVERSITY OF CHICAGO (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| WO-2013010573-A1 | COMPOUNDS WITH MATRIX-METALLOPROTEINASE INHIBITORY ACTIVITY | UNIVERSITAET MUENSTER (DE) | 2013-01-24 | — | — | WO | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2366704-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2364984-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-6492394-B1 | PROCOLLAGEN C-PROTEINASE INHIBITORS; TREATING FIBROTIC DISEASES | SYNTEX (U.S.A.) LLC | 2002-12-10 | — | — | US | disclosed |
| CN-1331674-A | Sulfonamide hydroxamates | HOFFMANN LA ROCHE (CH) | 2002-01-16 | — | — | CN | disclosed |
| EP-0813520-B1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER (US) | 2001-12-19 | — | — | EP | disclosed |
| EP-1149072-A1 | SULFONAMIDE HYDROXAMATES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| EP-1140846-A1 | ASPARTIC PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6114372-A | MATRIX METALLOPROTEINASE (MMP); TUMOR NECROSIS FACTOR(TNF); COMPOUNDS SUCH AS N2-((2S)-ACETYLMERCAPTO)ACETYL-5-PHTHALIMIDOPENTANOYL)-N1-((4 -METHOXYBENZENE)SULPHONYL)-N1-(PHENYLMETHYL)HYDRAZINE | DARWIN DISCOVERY LIMITED (GB) | 2000-09-05 | — | — | US | disclosed |
| WO-2000040558-A1 | ASPARTIC PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000037436-A1 | SULFONAMIDE HYDROXAMATES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| EP-0891328-A1 | PEPTIDYL COMPOUNDS HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997037973-A1 | PEPTIDYL COMPOUNDS HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227792-A1 | CARBORANE HYDROXAMIC ACID MATRIX METALLOPROTEINASE AGENTS FOR BORON NEUTRON CAPTURE THERAPY | MMP9, MMP26, MMP25 | MMP9 1/4885MMP2 9/4885MMP3 8/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | MMP9 245/4885MMP2 107/4885MMP3 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.